Literature DB >> 23724150

Clinical significance of discordant findings between pre-therapy (123)I and post-therapy (131)I whole body scan in patients with thyroid cancer.

Paco E Bravo1, Behnaz Goudarzi, Uzma Rana, Paulo Togni Filho, Raymond Castillo, Christopher Rababy, Marjorie Ewertz, Harvey A Ziessman, David S Cooper, Paul W Ladenson, Richard L Wahl.   

Abstract

Radioactive therapy with (131)I (RAI) is commonly used during the management of patients with differentiated thyroid cancer (DTC). The aim of this study was to determine the clinical significance of discordant findings between pre-RAI whole body scan (WBS) with (123)I and post-RAI WBS in the management of DTC. We retrospectively evaluated 342 individuals between 2002 and 2008 who had a diagnosis of DTC and underwent RAI. All had WBS one day before RAI and WBS one week after RAI. Patients were divided into 3 groups: 1) RAI-naive subjects without known distant metastatic disease (M1); 2) patients with history of prior RAI and persistent disease (except M1); and 3) patients with known M1. In Group 1 (n=311), 7% of patients (n=22) had discordant scans, but in only 4 of these cases did this represent true disease (3 unsuspected lung and 1 mediastinal node metastasis). In the remaining 18 patients, discordant findings corresponded to physiologic or other benign causes. In group 2 (n=23), 7 subjects (30%) had discordant findings and all of the discrepant sites consisted of loco-regional nodal disease in the neck/upper mediastinum (n=6) and M1 in lung (n=1). In group 3 (n=8), 5 patients (62%) showed discordant uptake in lung and bone which corresponded to the locations of known M1. A total of 12 patients with iodine-avid M1 were identified on post-RAI WBS (3.5% of entire cohort). Pre-RAI WBS was only concordant in 3 of these cases (25%). In conclusion, the significance of pre and post-RAI WBS is highly influenced by the clinical setting. Unsuspected distant metastatic disease is infrequent in RAI-naive patients without known M1, where most discordant findings are usually due to benign explanations, and represent false positive findings in this group. In contrast, in patients with history of previous RAI or known M1, discordant results likely correspond to true disease. In our study, pre-RAI scans showed a low yield to detect iodine-avid distant metastatic disease when compared to post-RAI scans.

Entities:  

Keywords:  Pre-therapy 123I scan; discordance; post-therapy 131I scan; thyroid cancer

Year:  2013        PMID: 23724150      PMCID: PMC3663998     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours.

Authors:  Stephen K Gerard; Ralph R Cavalieri
Journal:  Clin Nucl Med       Date:  2002-01       Impact factor: 7.794

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.

Authors:  S J Mandel; L K Shankar; F Benard; A Yamamoto; A Alavi
Journal:  Clin Nucl Med       Date:  2001-01       Impact factor: 7.794

4.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

5.  Bronchiectasis simulating pulmonary metastases on iodine-131 scintigraphy in well-differentiated thyroid carcinoma.

Authors:  Ian Jong; Kim Taubman; Stephen Schlicht
Journal:  Clin Nucl Med       Date:  2005-10       Impact factor: 7.794

6.  The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.

Authors:  A Siddiqi; R R Foley; K E Britton; A Sibtain; P N Plowman; A B Grossman; J P Monson; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  2001-10       Impact factor: 3.478

7.  123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.

Authors:  A S Alzahrani; S Bakheet; M Al Mandil; A Al-Hajjaj; A Almahfouz; A Al Haj
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

8.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.

Authors:  S I Sherman; E T Tielens; S Sostre; M D Wharam; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

9.  Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.

Authors:  Kevin P Donahue; Nirav P Shah; Stephanie L Lee; M Elizabeth Oates
Journal:  Radiology       Date:  2008-03       Impact factor: 11.105

10.  Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.

Authors:  Muammer Urhan; Simin Dadparvar; Ayse Mavi; Mohamed Houseni; Wichana Chamroonrat; Abass Alavi; Susan J Mandel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-26       Impact factor: 10.057

View more
  4 in total

Review 1.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

2.  Phoyunnanin E inhibits migration of non-small cell lung cancer cells via suppression of epithelial-to-mesenchymal transition and integrin αv and integrin β3.

Authors:  Nareerat Petpiroon; Boonchoo Sritularak; Pithi Chanvorachote
Journal:  BMC Complement Altern Med       Date:  2017-12-29       Impact factor: 3.659

3.  Effect of 131I 'clear residual thyroid tissue' after surgery on the function of parathyroid gland in differentiated thyroid cancer.

Authors:  Zhi-Hua Zhao; Feng-Qi Li; Jian-Kui Han; Xian-Jun Li
Journal:  Exp Ther Med       Date:  2015-10-19       Impact factor: 2.447

4.  Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?

Authors:  Elizabeth J de Koster; Taban Sulaiman; Jaap F Hamming; Abbey Schepers; Marieke Snel; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens
Journal:  Diagnostics (Basel)       Date:  2021-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.